Inclusion Criteria:

          1. Histologically or cytologically confirmed, Stage IIIB/IIIC or IV non-squamous NSCLC

          2. Participants with no EGFR, ALK and ROS1 mutation.

          3. Participants with no prior treatment for Stage IIIB/IIIC or IV non-squamous NSCLC

          4. Measurable disease as defined by RECIST v1.1

          5. Eastern Cooperative Oncology Group performance status 0 or 1

          6. Adequate hematologic and end organ function

        Exclusion Criteria:

          1. Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death treated with expected
             curative outcome

          2. Active central nervous system metastases

          3. Prior treatment with cluster of differentiation immune checkpoint blockade therapies
             or Bevacizumab

          4. Has received a surgical operation within 4 weeks from the initial drug administration

          5. Active or suspected autoimmune diseases. Subjects in a stable state with no need for
             systemic immunosuppressant therapy are allowed to enroll.

          6. Currently having or have had interstitial pneumonia, pneumoconiosis, radiation
             pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may
             interfere with the detection and management of suspected drug-related pulmonary
             toxicity

          7. Any active infection requiring systemic anti-infective therapy within 14 days prior to
             study drug administration

          8. Uncontrollable active infection(s)

          9. History of immunodeficiency, including HIV antibody positive

         10. active hepatitis B; or hepatitis C virus infections

         11. Has bleeding tendency

         12. History of severe cardiovascular diseases

         13. Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal
             fistula or abdominal abscess within 6 months before signing the informed consent;
             History of poorly controlled or recurrent inflammatory bowel disease; Active peptic
             ulcers, or > moderate esophageal varices

         14. Pregnant or breastfeeding female